Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it introduced a new gamma detection probe at the recent American College of Surgeons (ACS) 93rd Annual Clinical Congress meeting in San Francisco. The new probe is based on Bluetooth(R) wireless technology and is intended for use in laparoscopic procedures to communicate gamma radiation counts to the Company’s neoprobe(R) GDS or neo2000 gamma detection control units. The neoprobe GDS control unit contains internal circuitry that enables it to communicate with Neoprobe’s family of wireless probes without the necessity of an external adapter. However, the new wireless laparoscopic probe is designed to be compatible with all previous models of the Company’s neo2000 system (Models 2000, 2100 and 2200). Neoprobe’s wireless gamma detection products eliminate cumbersome cables that can unnecessarily complicate the surgical field. Neoprobe’s line of gamma detection systems are widely used by cancer surgeons in a procedure called Sentinel Lymph Node Biopsy (SLNB) or Intraoperative Lymphatic Mapping (ILM).
David Bupp, Neoprobe’s President and CEO, said, “We are excited by this new addition to our gamma detection product line that was well received at the ACS meeting. We believe this addition to our family of wireless gamma detection probes will offer the surgeon all of the advantages of a cordless instrument in minimally invasive laparoscopic procedures coupled with the already easy-to-use features of our existing control units. Because the wireless probe may be used with our existing installed base of neoprobe GDS and neo2000 system control units, we believe our current customers as well as those considering the purchase of a gamma detection system will be pleased. We expect that the first commercial shipments of the probe will occur during the fourth quarter of 2008. These wireless probes, coupled with our clinical development program for the lymphatic tissue tracing agent Lymphoseek(R), demonstrate Neoprobe’s commitment to assist physicians in providing state of the art treatment for cancer patients.”
About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000(R) line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix(R) line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek(R) and RIGScan(R) CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com
Comments